Clinical analysis of 21-gene relapse score test in hormone receptor-positive early-stage breast cancer

Mostrar otras versiones (1)

The 21-gene recurrence score (RS) predicts the prognosis of patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative early-stage breast cancer and the effectiveness of adding adjuvant chemotherapy on the basis of endocrine therapy to avoid excessive che...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Lizhe, Ma, Nan, Wang, Bin, Zhou, Can, Yan, Yu, Wang, Ke, He, Jianjun, Ren, Yu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2019
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6507352/
https://www.ncbi.nlm.nih.gov/pubmed/31186766
http://dx.doi.org/10.3892/ol.2019.10277

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6507352/
https://www.ncbi.nlm.nih.gov/pubmed/31186766
http://dx.doi.org/10.3892/ol.2019.10277

Ejemplares similares